J.Thaddeus Beck, MD, FACP

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab and berahyaluronidase for use across all adult and solid-tumor indications.